Top ▲

Primary progressive multiple sclerosis

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1235
Name:Primary progressive multiple sclerosis
Associated with:0 target
1 immuno-relevant ligand
Synonyms
PPMS | Primary-progressive MS
Description
This type of multiple sclerosis is characterized by steady worsening of neurologic functioning with no presentation of distinct relapses or periods of remission.
Database Links
Disease Ontology: DOID:0050784

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Primary progressive multiple sclerosis

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
ocrelizumab
Immuno Disease Comments: Ocrelizumab is approved to treat PPMS.
Clinical Use: The US FDA had granted breakthrough therapy designation for ocrelizumab for the treatment of primary progressive multiple sclerosis which converted to full FDA approval for the treatment of relapsing and primary progressive types of multiple sclerosis in March 2017. Phase 3 clinical trials identified that ocrelizumab produced a pronounced reduction of disease activity in multiple sclerosis patients [3].

Development of this antibody as a treatment for other inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, and B-cell malignancies has been suspended [1-2]. | View clinical data
Bioactivity Comments: Ocrelizumab depletes CD20+ B cells in the blood and lymphoid tissues of cynomolgus monkeys (Macaca fascicularis) [4]. B cell numbers recover to normal levels after one or two treatments [4]. Affinity data for clone 2H7.v16 is presented below. Clone 2H7.v31 exhibited 20-fold higher antibody-dependent cell-mediated cytotoxicity (ADCC) than the approved anti-CD20 monoclonal . | View biological activity

References

Show »

1. Hutas G. (2008) Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs, 9 (11): 1206-15. [PMID:18951300]

2. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther, 9 (7): 889-95. [PMID:19463076]

3. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B et al.. (2017) Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med, 376 (3): 209-220. [PMID:28002688]

4. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W et al.. (2005) Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother, 28 (3): 212-9. [PMID:15838377]